PUK18 - ECONOMIC EVALUATION OF THE USE OF SEVELAMER (RIFOSAR®) FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC RENAL DISEASE, FROM THE PERSPECTIVE OF THE INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.2816
https://www.valueinhealthjournal.com/article/S1098-3015(18)36118-7/fulltext
Section Title :
Section Order :
2168
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)36118-7&doi=10.1016/j.jval.2018.09.2816